×
About 2,830 results

ALLMedicine™ Anaplastic Large Cell Lymphoma Center

Research & Reviews  903 results

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT04447027

Jul 1st, 2022 - Background: Mature T-cell malignancies (TCM) are rare and heterogeneous group of leukemias and lymphomas accounting for 5 to 10% of all lymphomas in the US Patients with systemic TCM are most commonly treated with a CHOP (cyclophosphamide, doxorub...

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

Jul 1st, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxoru...

The Macro-textured Implant Recall: BIA-ALCL Risk Aversion in Cosmetic and Reconstructiv...
https://doi.org/10.1093/asj/sjac158
Aesthetic Surgery Journal; Mankowski P, Carr M et. al.

Jun 17th, 2022 - Since the association between anaplastic large cell lymphoma (ALCL) and textured breast implants has led to the recall of Allergan Biocell (Irvine, CA, USA) devices, plastic surgeons have been faced with the challenge of caring for patients with t...

CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth ...
https://doi.org/10.1038/s41375-022-01617-x 10.1038/nrc2291 10.3324/haematol.2009.014050 10.1182/blood-2005-10-014258 10.1371/journal.pone.0064544 10.1371/journal.pone.0117780 10.1016/j.ajpath.2012.01.008 10.1073/pnas.1009719107 10.1182/blood-2011-05-354654 10.1002/path.4171 10.1016/j.humpath.2014.06.012 10.1182/blood-2010-09-301994 10.1016/j.cell.2010.08.012 10.1016/j.biopha.2020.110099 10.1186/s12885-017-3132-9 10.1038/leu.2008.213 10.1038/leu.2011.168 10.1007/s12308-008-0020-x 10.1016/j.ymthe.2005.08.012 10.1126/science.1247005 10.1186/1476-4598-14-5 10.1016/S0091-679X(08)61072-9 10.2967/jnumed.114.138578 10.1021/acs.jproteome.6b00875 10.1002/bit.21747 10.1186/1752-0509-4-54 10.1007/s00204-015-1571-0 10.1021/ac401140h 10.1016/j.euf.2018.01.016 10.1038/s41590-020-0793-3 10.1016/j.visres.2017.03.009 10.18632/oncotarget.8153 10.1038/ncomms3236 10.1097/PAS.0000000000001820 10.3389/fimmu.2017.01931 10.1189/jlb.3RU0215-045R 10.1158/0008-5472.CAN-04-3605 10.1111/j.1440-1827.2006.01972.x 10.1016/j.jhep.2014.04.035 10.1007/s00262-019-02457-y 10.1093/emboj/19.15.3896 10.1167/iovs.02-0287 10.1158/0008-5472.CAN-14-2260 10.18632/oncotarget.2862 10.1038/ncomms4550 10.1038/emboj.2009.89 10.1042/bj20040095 10.1073/pnas.1117773108 10.1038/s41586-019-0945-5 10.1016/j.bbalip.2012.01.015 10.1111/febs.12015 10.1158/0008-5472.CAN-04-3605 10.1016/j.phrs.2016.11.022 10.1002/hep.21465 10.1089/cbr.2010.0801 10.18632/oncotarget.15709 10.1038/nm.4128
Leukemia Montes-Mojarro IA, Steinhilber J et. al.

Jun 9th, 2022 - We recently reported that miR-146a is differentially expressed in ALK+ and ALK- anaplastic large cell lymphoma (ALCL). In this study, the downstream targets of miR-146a in ALK+ ALCL were investigated by transcriptome analysis, identifying CD147 as...

Association of Silicone Breast Implant Reconstruction and -Enlargement With Overall Wellbeing, Lymphoma and Auto-immune Disease
https://clinicaltrials.gov/ct2/show/NCT05400954

Jun 7th, 2022 - There are various indications for implantation of a silicone breast implant. Most frequently, silicone breast implants are used in breast augmentation procedures for cosmetic reasons. In the field of oncology, breast implants are used for reconstr...

see more →

Guidelines  6 results

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2022.0015
Journal of the National Comprehensive Cancer Network : JN... Horwitz SM, Ansell S et. al.

Mar 12th, 2022 - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by ang...

UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic La...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894347
British Journal of Haematology; Turton P, El-Sharkawi D et. al.

Nov 23rd, 2020 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast sy...

American Registry of Pathology Expert Opinions: Recommendations for the diagnostic work...
https://doi.org/10.1016/j.anndiagpath.2020.151623
Annals of Diagnostic Pathology; Vega F, Amador C et. al.

Sep 19th, 2020 - The diagnosis of T-cell lymphomas is highly challenging and requires an integrated approach in which clinical, morphologic, immunophenotypic and molecular data are incorporated into the diagnosis. Under the auspices of the American Registry of Pat...

Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anap...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106983
Journal of Clinical Oncology : Official Journal of the Am... Jaffe ES, Ashar BS et. al.

Feb 12th, 2020 - To provide guidelines for the accurate pathologic diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected BIA-ALCL, and the pathologic evaluation of the capsulecto...

NCCN Consensus Guidelines for the Diagnosis and Management of Breast Implant-Associated...
https://doi.org/10.1093/asj/sjw259
Aesthetic Surgery Journal; Clemens MW, Horwitz SM

Feb 12th, 2017 - Published case series demonstrate a lack of treatment standardization for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) with a wide variety of therapeutic strategies being employed at all stages of disease. The National Compr...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  77 results

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT04447027

Jul 1st, 2022 - Background: Mature T-cell malignancies (TCM) are rare and heterogeneous group of leukemias and lymphomas accounting for 5 to 10% of all lymphomas in the US Patients with systemic TCM are most commonly treated with a CHOP (cyclophosphamide, doxorub...

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

Jul 1st, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxoru...

Association of Silicone Breast Implant Reconstruction and -Enlargement With Overall Wellbeing, Lymphoma and Auto-immune Disease
https://clinicaltrials.gov/ct2/show/NCT05400954

Jun 7th, 2022 - There are various indications for implantation of a silicone breast implant. Most frequently, silicone breast implants are used in breast augmentation procedures for cosmetic reasons. In the field of oncology, breast implants are used for reconstr...

Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults
https://clinicaltrials.gov/ct2/show/NCT01887522

May 31st, 2022 - Low grade gliomas (LGG) are the most frequent brain tumor type in children. They are often chemosensitive. However, more than 50% of these tumors will progress within the first 5 years after the start of the treatment and need a second-line therap...

Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)
https://clinicaltrials.gov/ct2/show/NCT00006455

May 31st, 2022 - OBJECTIVES: Compare the event-free survival in children with anaplastic large cell lymphoma treated with various induction and maintenance chemotherapy regimens with or without vinblastine. Compare the impact of different doses and schedules of me...

see more →

News  143 results

2021 Approvals Expand Access to Care for Patients Across Tumor Types
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....

Now Takeda Offers Rebate if Lung Cancer Drug Fails to Work
https://www.medscape.com/viewarticle/961710

Oct 27th, 2021 - Takeda Pharmaceuticals is now the latest pharmaceutical company to offer a value-based agreement on one of its new targeted therapies. The rebate offer is for brigatinib (Alunbrig) which is approved for the treatment of adults with anaplastic lymp...

T-Cell Lymphoma Options Burgeoning With Ongoing Clinical Trials
https://www.onclive.com/view/tcell-lymphoma-options-burgeoning-with-ongoing-clinical-trials

Oct 6th, 2021 - Steven Horwitz, MD Though T-cell lymphoma is a more rare hematologic malignancy, researchers are exploring therapies such as brentuximab vedotin (Adcetris) to improve outcomes for these patients. For example, the double-blind, randomized, multic...

Dr. Jagadeesh on Unmet Needs in Aggressive and Rare Lymphoma Subtypes
https://www.onclive.com/view/dr-jagadeesh-on-unmet-needs-in-aggressive-and-rare-lymphoma-subtypes

Oct 6th, 2021 - Deepa Jagadeesh, MD, associate staff, Department of Hematologic Oncology and Blood Disorders, Lymphoma and Bone Marrow Transplant Programs, Cleveland Clinic, discusses unmet needs in aggressive and rare lymphoma subtypes. Most available therapies...

FDA Grants Orphan Drug Designation to CFT7455 for Multiple Myeloma
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-cft7455-for-multiple-myeloma

Aug 17th, 2021 - The FDA has granted an orphan drug designation to CFT7455, a MonoDAC degrader targeting IKZF1/3, for use as a potential therapeutic option in patients with multiple myeloma, according to an announcement from C4 Therapeutics, Inc.1 We are pleased ...

see more →